I'm LongbridgeAI, I can summarize articles.Regeneron Pharma fell 5.59% this week to close at $781.49, while the S&P 500 lost 0.8%, leaving the stock to underperform by roughly 4.79 percentage points. The week opened higher and faded: Tuesday started at $814.36 and printed an intraday high of $821.17 before the shares slid into Friday’s low of $780.81. Volume declined across the four sessions, with the latest trading day at 444k shares, well below this week’s daily average of 537k.
The Week
Regeneron Pharma fell 5.59% this week to close at $781.49, while the S&P 500 lost 0.8%, leaving the stock to underperform by roughly 4.79 percentage points. The week opened higher and faded: Tuesday started at $814.36 and printed an intraday high of $821.17 before the shares slid into Friday’s low of $780.81. Volume declined across the four sessions, with the latest trading day at 444k shares, well below this week’s daily average of 537k.
Key Events
The week’s news centred on two threads: the Libtayo recall’s impact on the investment narrative, and a series of securities fraud class action reminders tied to disclosures about a key trial protocol and its ultimate failure. Pomerantz and Hagens Berman issued investor alerts pointing to a September 14 lead plaintiff deadline. Anchor Capital Advisors disclosed selling 8,418 shares, a minor position change. A Q2 biotech earnings recap noted commercial execution among innovators, but its direct link to Regeneron was limited.
Analyst Ratings
Coverage stands at 28 institutions: 14 rate it buy, 4 rate it overweight, 9 rate it hold, and 1 rates it underweight, with no sell ratings. The consensus recommendation is buy, with a consensus target of $849.32, implying upside of roughly 8.68% from the current price. The target range is wide, from $730 to $1,030, reflecting meaningful dispersion. Within the biotechnology industry, the stock ranks 6th on ratings.
The Week Ahead
A busy macro calendar lies ahead: the New York Fed manufacturing index on Tuesday, with a prior reading of 20.6 and a forecast of 14.75; then retail sales, retail sales ex autos, import prices, the NAHB housing market index, and EIA crude inventories on Wednesday. On the stock side, the September 14 lead plaintiff deadline has passed, so further disclosures around the class action bear watching.
In Short
Positive analyst ratings and a consensus target above spot sit against this week’s share price retreat, a wide target range, and the latest session’s flow pattern—small and medium orders as net buyers while large orders were net sellers. Valuation sits near 18.6x earnings and 2.5x book. The tension to monitor is whether litigation-related headlines keep weighing on sentiment, and whether the shares hold above this week’s lows.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.